CNPY2

Across TCGA pan-cancer cohorts, CNPY2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CNPY2 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CNPY2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CNPY2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and COAD show a favorable association.

CCRCC, UCEC, and COAD are the cancer types where CNPY2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.623	0.970	<.001	49	view →
UCEC	DFS	Quartile	All	1.000	0.687	.001	34	view →
COAD	DFS	Median	III,IV	1.000	0.779	.035	24	view →
LUAD	OS	Median	All	0.603	0.865	.010	14	view →
PDAC	DFS	Median	II,III,IV	0.479	0.266	.006	6	view →
GBM	DFS	Quartile	All	0.418	0.163	.049	2	view →
LSCC	DFS	Median	II,III,IV	0.666	0.870	.018	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CNPY2–CCRCC (DFS)

Open the CCRCC breakdown →